A lncRNA prognostic signature associated with immune infiltration and tumour mutation burden in breast cancer

J Cell Mol Med. 2020 Nov;24(21):12444-12456. doi: 10.1111/jcmm.15762. Epub 2020 Sep 23.

Abstract

Current studies have shown that long non-coding RNAs (lncRNAs) may serve as prognostic biomarkers in multiple cancers. Therefore, we postulated that expression patterns of multiple lncRNAs combined into a single signature could improve clinicopathological risk stratification and prediction of overall survival rate for breast cancer patients. Two algorithms, Least Absolute Shrinkage and Selector Operation (LASSO) and Support Vector Machine-Recursive Feature Elimination (SVM-RFE), were used to select candidate lncRNAs. Univariate and multivariate Cox regression analyses were employed to construct a seven-lncRNA signature for breast cancer. Stratified analysis revealed that the signature was significantly associated with multiple clinicopathological risk factors. For clinical use, we developed a nomogram model to predict overall survival and odds of death for breast cancer patients. Single-sample gene set enrichment analysis (ssGSEA), CIBERSORT algorithm and ESTIMATE method were employed to assess the relative immune cell infiltrations of each sample. Differentially infiltration of immune cells and diverse tumour mutation burden (TMB) scores might give rise to the efficacy of lncRNA signature for predicting the overall survival of patients. Correlation analysis implied that LINC01215 was associated with multiple immune-related signalling pathways. A seven-lncRNA prognostic signature is a reliable tool to predict the prognosis of breast cancer patients.

Keywords: bioinformatics; breast cancer; immune infiltration; lncRNA; prognosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Algorithms
  • Biomarkers, Tumor / genetics
  • Breast Neoplasms / genetics*
  • Breast Neoplasms / immunology*
  • Computational Biology
  • DNA Mutational Analysis
  • Female
  • Gene Expression Profiling
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Immune System
  • Kaplan-Meier Estimate
  • Multivariate Analysis
  • Mutation*
  • Nomograms
  • Odds Ratio
  • Predictive Value of Tests
  • Prognosis
  • Proportional Hazards Models
  • RNA, Long Noncoding / genetics*
  • Risk Factors
  • Signal Transduction
  • Support Vector Machine

Substances

  • Biomarkers, Tumor
  • RNA, Long Noncoding